Back to Search
Start Over
Short‐term intestinal lipase inhibition in normal‐weight individuals does not affect postprandial peptide YY <scp>3</scp> ‐36 and glucagon‐like peptide‐1 levels, hunger or satiety
- Source :
- Diabetes, Obesity and Metabolism. 22:2499-2503
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- Fat malabsorption associated with Roux-en-Y gastric bypass (RYGB) may contribute to elevated postprandial glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) after the procedure, leading to sustained weight loss and appetite reduction. This study investigated whether fat malabsorption via orlistat increases GLP-1 and PYY and if these increases would be proportional to changes in hunger and satiety. Five healthy participants received standardized meals with 120 mg orlistat or placebo in a randomized, double-blinded, crossover design for 3 days. On the final day, glucose, insulin, GLP-1, PYY3-36 and visual analogue scores for hunger and satiety were measured over a 14-hour period that included three meals. Fasting, 14-hour area under the curve (AUC) and meal-related AUC for glucose and insulin were similar, although postprandial increases in peak insulin and glucose were greater with orlistat. PYY3-36 , GLP-1, hunger and satiety were not different. In conclusion, short-term orlistat administration does not enhance postprandial GLP-1 or PYY3-36 or affect hunger or satiety in normal-weight individuals. Furthermore, fat malabsorption from RYGB is unlikely to mediate subsequent postprandial increases in GLP-1 and PYY.
- Subjects :
- medicine.medical_specialty
Endocrinology, Diabetes and Metabolism
medicine.medical_treatment
media_common.quotation_subject
030209 endocrinology & metabolism
030204 cardiovascular system & hematology
03 medical and health sciences
0302 clinical medicine
Endocrinology
Weight loss
Internal medicine
Internal Medicine
medicine
media_common
business.industry
Insulin
digestive, oral, and skin physiology
Appetite
Glucagon-like peptide-1
Fat malabsorption
Orlistat
Postprandial
Peptide YY
medicine.symptom
business
hormones, hormone substitutes, and hormone antagonists
medicine.drug
Subjects
Details
- ISSN :
- 14631326 and 14628902
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- Diabetes, Obesity and Metabolism
- Accession number :
- edsair.doi...........4f7d4873fc0b1ce578f3f413a709dcd0